1-3 of 3
Stephen K. Tahir, PhD
Close
Sort by
Journal Articles

The Combinatorial Activity of Eftozanermin (ABBV-621), a Novel and Potent TRAIL Receptor Agonist Fusion Protein, in Pre-Clinical Models of Hematologic Malignancies

Morey L Smith, MS, Sha Jin, MS, Dong Chen, MS, Haichao Zhang, PhD, Jason Huska, PhD, Deborah Widomski, Vicky Bontcheva, Greg Buchanan, PhD, Susan Morgan-Lappe, PhD, Darren C. Phillips, PhD, Stephen K Tahir, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 41.
https://doi.org/10.1182/blood-2020-136155
Published: 2020
Journal Articles

CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1

Jun Chen, MDPhD, Sha Jin, MS, Paul Tapang, Stephen K Tahir, PhD, Morey Smith, John Xue, Haichao Zhang, PhD, Wenqing Gao, PhD, Yunsong Tong, PhD, Richard Clark, Justin L. Ricker, MD PhD, Thomas D Penning, PhD, Daniel H Albert, PhD, Darren C Phillips, PhD, Andrew J Souers, PhD, Joel D. Leverson, PhD
Journal: Blood
Blood (2014) 124 (21): 2161.
https://doi.org/10.1182/blood.V124.21.2161.2161
Published: 2014
Journal Articles

The Bcl-2 Family Protein Inhibitor, ABT-263, Promotes Apoptotic-Like Response in Isolated Platelets.

Chris Tse, PhD, Haichao Zhang, PhD, Jun Chen, PhD, Ryan M. Fryer, PhD, Richard Nelson, Paul Nimmer, Glenn A. Reinhart, PhD, Morey L. Smith, Stephen K. Tahir, PhD, Saul H. Rosenberg, PhD, Steven W. Elmore, PhD
Journal: Blood
Blood (2006) 108 (11): 1122.
https://doi.org/10.1182/blood.V108.11.1122.1122
Published: 2006